Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients

Eleftheria Kampouri, Elizabeth M. Krantz, Hu Xie, Sarah S. Ibrahimi, Erika S. Kiem, Mandeep K. Sekhon, Emily C. Liang, Andrew J. Cowan, Andrew Portuguese, Damian J. Green, Aya Albittar, Jennifer J. Huang, Jordan Gauthier, Ailyn C. Pérez-Osorio, Keith R. Jerome, Danielle M. Zerr, Michael J. Boeckh, Joshua A. Hill

Blood (2024) 144 (5): 490–495.

https://doi.org/10.1182/blood.2024024145

Published: 2024

Includes: Supplemental data

Journal Articles

How I use next-generation sequencing–MRD to plan approach and prevent relapse after HCT for children and adults with ALL

Lori Muffly, Emily C. Liang, J. Gregory Dolan, Michael A. Pulsipher

Blood (2024) 144 (3): 253–261.

https://doi.org/10.1182/blood.2023023699

Published: 2024

Journal Articles

Day +3/Day 0 Ferritin Ratio: A Simple Point-of-Care Index Predictive of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome after CD19 CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 3495.

https://doi.org/10.1182/blood-2023-182597

Published: 2023

Journal Articles

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 2143.

https://doi.org/10.1182/blood-2023-174106

Published: 2023

Journal Articles

Phase I/II Study to Evaluate the Safety, Feasibility, and Efficacy of FP-1201 (Intravenous Interferon-Beta-1a) to Prevent Toxicities after CD19-Directed CAR T-Cell Therapy: Trial in Progress

Emily C Liang, Erik L Kimble, Aya Albittar, Jennifer J. Huang, Andrew J Portuguese, Aiko Torkelson, Delaney Kirchmeier, Abigail Chutnik, Barbara Pender, Sylvain Simon, Tony Chour, Evan W. Newell, Rahul Banerjee, David G Maloney, Alexander Spicer, Juho Jalkanen, Alexandre V Hirayama, Jordan Gauthier

Blood (2023) 142 (Supplement 1): 4860.

https://doi.org/10.1182/blood-2023-173152

Published: 2023

Journal Articles

Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel

Aya Albittar, Jenna M Voutsinas, Andrew J Portuguese, Jennifer J. Huang, Emily C Liang, Qian Wu, Xinyi Fan, Alexandre V Hirayama, Erik L Kimble, Lorenzo Iovino, Christina Poh, Ajay K Gopal, Mazyar Shadman, Brian G Till, Filippo Milano, Aude G Chapuis, Ryan D Cassaday, David G Maloney, Jordan Gauthier

Blood (2023) 142 (Supplement 1): 2126.

https://doi.org/10.1182/blood-2023-180128

Published: 2023

Journal Articles

Retrospective Analysis of Adolescent Young Adult Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated with the CALGB 10403 Regimen Since Completion of Trial Enrollment

Brandon DaSilva, Rutu D. Vyas, Alicia Darwin, Kathryn Russel, Jason Gilbert, Virginia Tan, Himani Darji, Katharine Miller, Emily C Liang, Suravi Raychaudhuri, Adam S. Duvall, Michaela Liedtke, Wendy Stock, Ryan Cassaday, Marc Schwartz, Jessica T. Leonard, Marlise R. Luskin, Lori S. Muffly

Blood (2023) 142 (Supplement 1): 4240.

https://doi.org/10.1182/blood-2023-185176

Published: 2023

Journal Articles

Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting

Andrew J Portuguese, Aya Albittar, Emily C Liang, Jennifer J. Huang, Alexandre V Hirayama, Erik L Kimble, Lorenzo Iovino, Christina Poh, Ajay K Gopal, Mazyar Shadman, Brian G Till, Hans-Peter Kiem, Filippo Milano, Aude G Chapuis, Folashade Otegbeye, Ryan D Cassaday, David G Maloney, Jordan Gauthier

Blood (2023) 142 (Supplement 1): 2131.

https://doi.org/10.1182/blood-2023-172978

Published: 2023

Journal Articles

Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis

Blood (2023) 142 (Supplement 1): 6848.

https://doi.org/10.1182/blood-2023-172695

Published: 2023

Journal Articles

Phase 2 Study of CD19 CAR T Cells with a Fully Human Binder for Large B-Cell Lymphoma in Relapse or Progression after a Murine Binder-Bearing CD19 CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 6860.

https://doi.org/10.1182/blood-2023-181273

Published: 2023

Journal Articles

Oxidative DNA damage in reconstituting T cells is associated with relapse and inferior survival after allo-SCT

F. Karl, C. Liang, R. Böttcher-Loschinski, A. Stoll, C. Flamann, S. Richter, C. Lischer, S. Völkl, B. Jacobs, M. Böttcher, R. Jitschin, H. Bruns, T. Fischer, E. Holler, W. Rösler, T. Dandekar, A. Mackensen, D. Mougiakakos

Blood (2023) 141 (13): 1626–1639.

https://doi.org/10.1182/blood.2022017267

Published: 2023

Includes: Supplemental data

Journal Articles

Ultra-Sensitive Next-Generation Sequencing Establishes the Prognostic Value of Very Low MRD in Adults with Acute Lymphoblastic Leukemia Undergoing Hematopoietic Cell Transplantation

Emily C. Liang, Simone E. Dekker, Jean M.G. Sabile, Stefan Torelli, Amy Zhang, Katharine Miller, Parveen Shiraz, Brandon Hayes-Lattin, Jessica Leonard, Lori Muffly

Blood (2022) 140 (Supplement 1): 1732–1733.

https://doi.org/10.1182/blood-2022-157442

Published: 2022

Journal Articles

Self-Reported Experiences of Adult Hematopoietic Cell Transplantation Survivors with COVID-19 Vaccination and Infection

Emily C. Liang, Lynn E. Onstad, Paul A. Carpenter, Steven A. Pergam, Stephanie J. Lee, Catherine Liu

Blood (2022) 140 (Supplement 1): 920–921.

https://doi.org/10.1182/blood-2022-157440

Published: 2022

Journal Articles

Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD Mutated AML Following Allogeneic Hematopoietic Cell Transplantation

Emily C. Liang, Connie Chen, Rong Lu, Gabriel N. Mannis, Lori Muffly

Blood (2021) 138 (Supplement 1): 1306.

https://doi.org/10.1182/blood-2021-149805

Published: 2021

Journal Articles

Organ Damage at Initial Presentation across the Spectrum of Advanced Systemic Mastocytosis Variants

Emily C. Liang, Cecelia Perkins, Rong Lu, Justin Abuel, Cheryl Langford, Denise DeVore, Lenn Fechter, Parveen Abidi, William Shomali, Jason Gotlib

Blood (2021) 138 (Supplement 1): 2567.

https://doi.org/10.1182/blood-2021-145082

Published: 2021

Journal Articles

High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6 -deregulating mutations, in gastric lymphoma

Yun-Wen Chen, Xiao-Tong Hu, Anthony C. Liang, Wing-Yan Au, Chi-Chiu So, Michelle L. Wong, Lijun Shen, Qian Tao, Kent-Man Chu, Yok-Lam Kwong, Raymond H. Liang, Gopesh Srivastava

Blood (2006) 108 (7): 2373–2383.

https://doi.org/10.1182/blood-2006-05-022517

Published: 2006

Includes: Supplemental data

Journal Articles

Deletions of chromosome 5q13.3 and 17p loci cooperate in myeloid neoplasms

Patricia D. Castro, Jan C. Liang, Lalitha Nagarajan

Blood (2000) 95 (6): 2138–2143.

https://doi.org/10.1182/blood.V95.6.2138

Published: 2000

Journal Articles

Use of Leukemic Dendritic Cells for the Generation of Antileukemic Cellular Cytotoxicity Against Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia

Aniruddha Choudhury, James L. Gajewski, Jan C. Liang, Uday Popat, David F. Claxton, Kay-Oliver Kliche, Michael Andreeff, Richard E. Champlin

Blood (1997) 89 (4): 1133–1142.

https://doi.org/10.1182/blood.V89.4.1133

Published: 1997

NARROW

Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients

How I use next-generation sequencing–MRD to plan approach and prevent relapse after HCT for children and adults with ALL

Day +3/Day 0 Ferritin Ratio: A Simple Point-of-Care Index Predictive of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome after CD19 CAR T-Cell Therapy

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Phase I/II Study to Evaluate the Safety, Feasibility, and Efficacy of FP-1201 (Intravenous Interferon-Beta-1a) to Prevent Toxicities after CD19-Directed CAR T-Cell Therapy: Trial in Progress

Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel

Retrospective Analysis of Adolescent Young Adult Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated with the CALGB 10403 Regimen Since Completion of Trial Enrollment

Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting

Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis

Phase 2 Study of CD19 CAR T Cells with a Fully Human Binder for Large B-Cell Lymphoma in Relapse or Progression after a Murine Binder-Bearing CD19 CAR T-Cell Therapy

Oxidative DNA damage in reconstituting T cells is associated with relapse and inferior survival after allo-SCT

Ultra-Sensitive Next-Generation Sequencing Establishes the Prognostic Value of Very Low MRD in Adults with Acute Lymphoblastic Leukemia Undergoing Hematopoietic Cell Transplantation

Self-Reported Experiences of Adult Hematopoietic Cell Transplantation Survivors with COVID-19 Vaccination and Infection

Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD Mutated AML Following Allogeneic Hematopoietic Cell Transplantation

Organ Damage at Initial Presentation across the Spectrum of Advanced Systemic Mastocytosis Variants

High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6 -deregulating mutations, in gastric lymphoma

Deletions of chromosome 5q13.3 and 17p loci cooperate in myeloid neoplasms

Use of Leukemic Dendritic Cells for the Generation of Antileukemic Cellular Cytotoxicity Against Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only